Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ipratropium bromide
Form:
16 of 16 products shown
2 general benefit · 8 Limited Use · 6 not a benefit
PMS-Ipratropium · DIN 02239627 · 0.03% · Nasal Spray
Limited Use, Reason for Use code 03 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 03 required
Write on scriptReason for Use code 03 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 03
Reason for Use code 03
For the treatment of non-allergic vasomotor rhinitis
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
PMS-Ipratropium · DIN 02239627
Manufacturer: Pharmascience Inc.; listing date 2000-07-17
Health Canada: Marketed since 1999-04-15 · brand PMS-IPRATROPIUM · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Nasal · ingredients IPRATROPIUM BROMIDE 21 MCG/ACT · company Pharmascience inc · schedule Prescription
PMS-Ipratropium: Formulary list price $0.91 per unit (the source does not state the unit; exact figure $0.9127). What the ministry pays, not the patient.
DIN 02239627: PMS-Ipratropium
Raw flags: sec12=Y, sec3=Y
Item: 523600082; group id 626; item number 1595; lccId 00088; manufacturer id PMS
Source form: Nasal Spray; strength: 0.03%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.9127; ministry $0.9127
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02239627
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63098Interchangeable products
Atrovent · DIN 02163705 · not recorded
Shortage status: resolved shortage (ended January 8, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02239627
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Atrovent HFA · DIN 02247686
Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2004-11-04
Health Canada: Marketed since 2004-03-24 · brand ATROVENT HFA · ATC R03BB01 IPRATROPIUM BROMIDE · form Aerosol (metered-dose) · route Inhalation · ingredients IPRATROPIUM BROMIDE 20 MCG/ACT · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
DIN 02247686: Atrovent HFA
Raw flags: sec3=Y
Item: 120800056; group id 207; item number 0377; lccId None; manufacturer id BOE
Source form: Inh-200 Dose Pk; strength: 20mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $21.3600; ministry $11.2530
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247686
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71950Interchangeable products
Jamp Ipratropium HFA · DIN 02542587 · $11.2530
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247686
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Jamp Ipratropium HFA · DIN 02542587
Manufacturer: Jamp Pharma Corporation; listing date 2024-09-27
Health Canada: Marketed since 2024-08-15 · brand JAMP IPRATROPIUM HFA · ATC R03BB01 IPRATROPIUM BROMIDE · form Aerosol (metered-dose) · route Inhalation · ingredients IPRATROPIUM BROMIDE 20 MCG/ACT · company Jamp pharma corporation · schedule Prescription
Jamp Ipratropium HFA: Formulary list price $11.25 per unit (the source does not state the unit; exact figure $11.2530). What the ministry pays, not the patient.
DIN 02542587: Jamp Ipratropium HFA
Raw flags: sec3=Y
Item: 120800056; group id 207; item number 0377; lccId None; manufacturer id JPC
Source form: Inh-200 Dose Pk; strength: 20mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $11.2530; ministry $11.2530
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02542587
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103113Interchangeable products
Atrovent HFA · DIN 02247686 · $11.2530
Shortage status: resolved shortage (ended June 16, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02542587
Limited Use, Reason for Use code 265, 266, 267, 268 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Ipratropium · DIN 02231135
Manufacturer: Pharmascience Inc.; listing date 1999-04-15
Health Canada: Marketed since 2001-06-08 · brand PMS-IPRATROPIUM · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 125 MCG/ML · company Pharmascience inc · schedule Prescription
PMS-Ipratropium: Formulary list price $1.15 per unit (the source does not state the unit; exact figure $1.1505). What the ministry pays, not the patient.
DIN 02231135: PMS-Ipratropium
Raw flags: sec12=Y, sec3=Y
Item: 120800047; group id 206; item number 0375; lccId 00031; manufacturer id PMS
Source form: Inh Sol-2mL UDV Pk; strength: 125mcg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.1505; ministry $1.1505
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02231135
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50442Interchangeable products
Atrovent UDV · DIN 02026759 · not recorded
Shortage status: resolved shortage (ended August 15, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02231135
Limited Use, Reason for Use code 256, 257, 258, 259 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 256
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 257
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 258
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 259
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
AA-Ipravent · DIN 02126222
Manufacturer: A A Pharma Inc.; listing date 2000-11-30
Health Canada: Marketed since 2024-03-28 · brand AA-IPRAVENT · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Aa pharma inc · schedule Prescription
DIN 02126222: AA-Ipravent
Raw flags: sec12=Y, sec3=Y
Item: 120800039; group id 205; item number 0374; lccId 00030; manufacturer id AAP
Source form: Inh Sol-20mL Pk; strength: 250mcg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $6.3140; ministry $6.3140
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02126222
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16947Interchangeable products
Atrovent · DIN 00731439 · not recorded
Novo-Ipramide · DIN 02210479 · $6.3140
PMS-Ipratropium · DIN 02231136 · $6.3140
Shortage status: resolved shortage (ended March 25, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02126222
Limited Use, Reason for Use code 265, 266, 267, 268 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Ipratropium · DIN 02231245
Manufacturer: Pharmascience Inc.; listing date 1999-04-15
Health Canada: Marketed since 1997-10-29 · brand PMS-IPRATROPIUM · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Pharmascience inc · schedule Prescription
PMS-Ipratropium: Formulary list price $1.32 per unit (the source does not state the unit; exact figure $1.3180). What the ministry pays, not the patient.
DIN 02231245: PMS-Ipratropium
Raw flags: sec12=Y, sec3=Y
Item: 120800046; group id 206; item number 0376; lccId 00031; manufacturer id PMS
Source form: Inh Sol-2mL UDV Pk; strength: 250mcg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.3180; ministry $1.3180
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02231245
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50552Interchangeable products
Atrovent UDV · DIN 01950681 · not recorded
Ratio-Ipratropium UDV · DIN 02097168 · $1.3180
Teva-Ipratropium Sterinebs · DIN 02216221 · $1.3180
Shortage status: resolved shortage (ended November 28, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02231245
Limited Use, Reason for Use code 265, 266, 267, 268 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Ipratropium Sterinebs · DIN 02216221
Manufacturer: Teva Canada Limited; listing date 1999-09-15
Health Canada: Marketed since 2012-07-12 · brand TEVA-IPRATROPIUM STERINEBS · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Teva canada limited · schedule Prescription
Teva-Ipratropium Sterinebs: Formulary list price $1.32 per unit (the source does not state the unit; exact figure $1.3180). What the ministry pays, not the patient.
DIN 02216221: Teva-Ipratropium Sterinebs
Raw flags: sec12=Y, sec3=Y
Item: 120800046; group id 206; item number 0376; lccId 00031; manufacturer id TEV
Source form: Inh Sol-2mL UDV Pk; strength: 250mcg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.3180; ministry $1.3180
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02216221
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43176Interchangeable products
Atrovent UDV · DIN 01950681 · not recorded
PMS-Ipratropium · DIN 02231245 · $1.3180
Ratio-Ipratropium UDV · DIN 02097168 · $1.3180
Shortage status: resolved shortage (ended June 16, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02216221
Shortage record checked October 6, 2026
Ipravent · DIN 02246084 · 0.06% · Nasal Spray
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Ipravent · DIN 02246084
Manufacturer: A A Pharma Inc.; listing date 2009-06-23
Health Canada: Marketed since 2014-05-28 · brand IPRAVENT · ATC R01AX03 IPRATROPIUM BROMIDE · form Solution · route Nasal · ingredients IPRATROPIUM BROMIDE 42 MCG/ACT · company Aa pharma inc · schedule Prescription
DIN 02246084: Ipravent
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 523600117; group id 627; item number 1596; lccId None; manufacturer id AAP
Source form: Nasal Spray; strength: 0.06%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $2.9700; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02246084
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70219Interchangeable products
Atrovent · DIN 02163713 · not recorded
Shortage status: active shortage (reported August 25, 2026, estimated to end October 30, 2026, last updated September 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246084
Limited Use, Reason for Use code 256, 257, 258, 259 requiredDormant since August 1, 2025 · checked October 5, 2026 · What does dormant mean?
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 256
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 257
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 258
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 259
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Ipratropium · DIN 02231136
Manufacturer: Pharmascience Inc.; listing date 1999-04-15
Health Canada: Dormant since 2025-08-01 · brand PMS-IPRATROPIUM · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Pharmascience inc · schedule Prescription
PMS-Ipratropium: Formulary list price $6.31 per unit (the source does not state the unit; exact figure $6.3140). What the ministry pays, not the patient.
DIN 02231136: PMS-Ipratropium
Raw flags: sec12=Y, sec3=Y
Item: 120800039; group id 205; item number 0374; lccId 00030; manufacturer id PMS
Source form: Inh Sol-20mL Pk; strength: 250mcg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $6.3140; ministry $6.3140
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02231136
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50443Interchangeable products
AA-Ipravent · DIN 02126222 · $6.3140
Atrovent · DIN 00731439 · not recorded
Novo-Ipramide · DIN 02210479 · $6.3140
Shortage status: resolved shortage (ended June 26, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02231136
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 1, 2025 — choose a marketed DIN from the same-category list.
Limited Use, Reason for Use code 256, 257, 258, 259 required; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.Discontinued October 26, 2015 · checked October 5, 2026
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below); Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 256
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 257
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 258
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 259
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Novo-Ipramide · DIN 02210479
Manufacturer: Novopharm Ltd.; listing date 1999-04-15
Health Canada: Cancelled post market since 2015-10-26 · brand NOVO-IPRAMIDE - LIQ 0.25MG/ML · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE .25 MG/ML · company Novopharm limited · schedule Prescription
Novo-Ipramide: Formulary list price $6.31 per unit (the source does not state the unit; exact figure $6.3140). What the ministry pays, not the patient.
DIN 02210479: Novo-Ipramide
Raw flags: sec12=Y, sec3=Y
Item: 120800039; group id 205; item number 0374; lccId 00030; manufacturer id NOP
Source form: Inh Sol-20mL Pk; strength: 250mcg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $6.3140; ministry $6.3140
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02210479
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20153Interchangeable products
AA-Ipravent · DIN 02126222 · $6.3140
Atrovent · DIN 00731439 · not recorded
PMS-Ipratropium · DIN 02231136 · $6.3140
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02210479
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since October 26, 2015 — choose a marketed DIN from the same-category list.
Limited Use, Reason for Use code 265, 266, 267, 268 required; Health Canada lists this DIN as Cancelled post market since 2018-05-18 — choose a marketed DIN from the same-category list.Discontinued May 18, 2018 · checked October 5, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required; Health Canada lists this DIN as Cancelled post market since 2018-05-18 — choose a marketed DIN from the same-category list.
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below); Health Canada lists this DIN as Cancelled post market since 2018-05-18 — choose a marketed DIN from the same-category list.
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Ratio-Ipratropium UDV · DIN 02097168
Manufacturer: Ratiopharm Inc.; listing date 1996-12-19
Health Canada: Cancelled post market since 2018-05-18 · brand RATIO-IPRATROPIUM UDV · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Teva canada limited · schedule Prescription
Ratio-Ipratropium UDV: Formulary list price $1.32 per unit (the source does not state the unit; exact figure $1.3180). What the ministry pays, not the patient.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02097168).
DIN 02097168: Ratio-Ipratropium UDV
Raw flags: dinStatus=E, sec12=Y, sec3=Y
Item: 120800046; group id 206; item number 0376; lccId 00031; manufacturer id RPH
Source form: Inh Sol-2mL UDV Pk; strength: 250mcg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; DIN status E, meaning unconfirmed
Source prices (unrounded): $1.3180; ministry $1.3180
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02097168
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19798Interchangeable products
Atrovent UDV · DIN 01950681 · not recorded
PMS-Ipratropium · DIN 02231245 · $1.3180
Teva-Ipratropium Sterinebs · DIN 02216221 · $1.3180
Shortage status: resolved shortage (ended September 1, 2017); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02097168
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since May 18, 2018 — choose a marketed DIN from the same-category list.
Atrovent · DIN 02163705 · 0.03% · Nasal Spray
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-11-13 — choose a marketed DIN from the same-category list.Discontinued November 13, 2018 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-11-13 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-11-13 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 03
Reason for Use code 03
For the treatment of non-allergic vasomotor rhinitis
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Atrovent · DIN 02163705
Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 1996-10-01
Health Canada: Cancelled post market since 2018-11-13 · brand ATROVENT NASAL SPRAY · ATC R01AX03 IPRATROPIUM BROMIDE · form Solution · route Nasal · ingredients IPRATROPIUM BROMIDE 21 MCG/ACT · company Sanofi-aventis canada inc · schedule Prescription
DIN 02163705: Atrovent
Raw flags: notABenefit=Y, sec3=Y
Item: 523600082; group id 626; item number 1595; lccId 00088; manufacturer id BOE
Source form: Nasal Spray; strength: 0.03%
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02163705
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19245Interchangeable products
PMS-Ipratropium · DIN 02239627 · $0.9127
Shortage status: discontinued (October 4, 2018, reported by SANOFI-AVENTIS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02163705
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 13, 2018 — choose a marketed DIN from the same-category list.
Atrovent · DIN 02163713 · 0.06% · Nasal Spray
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-11-13 — choose a marketed DIN from the same-category list.Discontinued November 13, 2018 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-11-13 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-11-13 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Atrovent · DIN 02163713
Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2009-06-23
Health Canada: Cancelled post market since 2018-11-13 · brand ATROVENT NASAL SPRAY · ATC R01AX03 IPRATROPIUM BROMIDE · form Solution · route Nasal · ingredients IPRATROPIUM BROMIDE 42 MCG/ACT · company Sanofi-aventis canada inc · schedule Prescription
DIN 02163713: Atrovent
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 523600117; group id 627; item number 1596; lccId None; manufacturer id BOE
Source form: Nasal Spray; strength: 0.06%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02163713
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19651Interchangeable products
Ipravent · DIN 02246084 · not recorded
Shortage status: discontinued (November 13, 2018, reported by SANOFI-AVENTIS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02163713
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 13, 2018 — choose a marketed DIN from the same-category list.
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-09-18 — choose a marketed DIN from the same-category list.Discontinued September 18, 2008 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-09-18 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2008-09-18 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Atrovent UDV · DIN 02026759
Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 1996-10-01
Health Canada: Cancelled post market since 2008-09-18 · brand ATROVENT UDV 125MCG/ML · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation, Oral · ingredients IPRATROPIUM BROMIDE 125 MCG/ML · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Atrovent UDV: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 02026759: Atrovent UDV
Raw flags: notABenefit=Y, sec3=Y
Item: 120800047; group id 206; item number 0375; lccId 00031; manufacturer id BOE
Source form: Inh Sol-2mL UDV Pk; strength: 125mcg/mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02026759
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14203Interchangeable products
PMS-Ipratropium · DIN 02231135 · $1.1505
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02026759
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 18, 2008 — choose a marketed DIN from the same-category list.
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-10-11 — choose a marketed DIN from the same-category list.Discontinued October 11, 2007 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-10-11 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2007-10-11 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 256
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 257
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 258
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 259
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Atrovent · DIN 00731439
Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 1996-10-01
Health Canada: Cancelled post market since 2007-10-11 · brand ATROVENT · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
DIN 00731439: Atrovent
Raw flags: notABenefit=Y, sec3=Y
Item: 120800039; group id 205; item number 0374; lccId 00030; manufacturer id BOE
Source form: Inh Sol-20mL Pk; strength: 250mcg/mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00731439
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8525Interchangeable products
AA-Ipravent · DIN 02126222 · $6.3140
Novo-Ipramide · DIN 02210479 · $6.3140
PMS-Ipratropium · DIN 02231136 · $6.3140
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00731439
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since October 11, 2007 — choose a marketed DIN from the same-category list.
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-04-16 — choose a marketed DIN from the same-category list.Discontinued April 16, 2008 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-04-16 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2008-04-16 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Atrovent UDV · DIN 01950681
Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 1996-10-01
Health Canada: Cancelled post market since 2008-04-16 · brand ATROVENT UDV SOL INH 250MCG/ML · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Atrovent UDV: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 01950681: Atrovent UDV
Raw flags: notABenefit=Y, sec3=Y
Item: 120800046; group id 206; item number 0376; lccId 00031; manufacturer id BOE
Source form: Inh Sol-2mL UDV Pk; strength: 250mcg/mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01950681
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12454Interchangeable products
PMS-Ipratropium · DIN 02231245 · $1.3180
Ratio-Ipratropium UDV · DIN 02097168 · $1.3180
Teva-Ipratropium Sterinebs · DIN 02216221 · $1.3180
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01950681
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 16, 2008 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (R03BB): coverage varies; not interchangeable
Aclidinium (Tudorza Genuair): general benefit
Glycopyrronium (Seebri Breezhaler): general benefit
Tiotropium (Spiriva): general benefit
Umeclidinium (Incruse Ellipta): general benefit
Ipratropium bromide/salbutamol
2 Limited Use · 1 not a benefit
Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 · 500 mcg/2.5 mg/2.5 mL · Inh Sol-2.5mL Amp Pk
Limited Use, Reason for Use code 256, 257, 258, 259 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 256
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 257
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 258
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 259
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Ipratropium Bromide and Salbutamol Sulph · DIN 02483394
Manufacturer: MDA Inc.; listing date 2019-12-20
Health Canada: Marketed since 2026-08-28 · brand IPRATROPIUM BROMIDE AND SALBUTAMOL SULPHATE INHALATION SOLUTION · ATC R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE, R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE, R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 0.5 MG/2.5ML, SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Juno pharma canada inc. · schedule Prescription
Ipratropium Bromide and Salbutamol Sulph: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8066). What the ministry pays, not the patient.
DIN 02483394: Ipratropium Bromide and Salbutamol Sulph
Raw flags: sec12=Y, sec3=Y
Item: 120800050; group id 208; item number 0378; lccId 00029; manufacturer id MDI
Source form: Inh Sol-2.5mL Amp Pk; strength: 500mcg/2.5mg/2.5mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.8066; ministry $0.8066
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02483394
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97384Interchangeable products
Combivent UDV · DIN 02231675 · not recorded
Teva-Combo Sterinebs · DIN 02272695 · $0.8066
Shortage status: resolved shortage (ended April 16, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02483394
Shortage record checked October 6, 2026
Teva-Combo Sterinebs · DIN 02272695 · 500 mcg/2.5 mg/2.5 mL · Inh Sol-2.5mL Amp Pk
Limited Use, Reason for Use code 256, 257, 258, 259 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 256
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 257
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 258
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 259
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Combo Sterinebs · DIN 02272695
Manufacturer: Teva Canada Limited; listing date 2006-01-24
Health Canada: Marketed since 2012-07-17 · brand TEVA-COMBO STERINEBS · ATC R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE, R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 0.5 MG/2.5ML, SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Teva canada limited · schedule Prescription
Teva-Combo Sterinebs: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8066). What the ministry pays, not the patient.
DIN 02272695: Teva-Combo Sterinebs
Raw flags: sec12=Y, sec3=Y
Item: 120800050; group id 208; item number 0378; lccId 00029; manufacturer id TEV
Source form: Inh Sol-2.5mL Amp Pk; strength: 500mcg/2.5mg/2.5mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.8066; ministry $0.8066
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02272695
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75820Interchangeable products
Combivent UDV · DIN 02231675 · not recorded
Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 · $0.8066
Shortage status: resolved shortage (ended April 3, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02272695
Shortage record checked October 6, 2026
Combivent UDV · DIN 02231675 · 500 mcg/2.5 mg/2.5 mL · Inh Sol-2.5mL Amp Pk
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-01-08 — choose a marketed DIN from the same-category list.Discontinued January 8, 2020 · checked November 18, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-01-08 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-01-08 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 256
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 257
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 258
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 259
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Combivent UDV · DIN 02231675
Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 1998-12-31
Health Canada: Cancelled post market since 2020-01-08 · brand COMBIVENT UDV · ATC R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 0.5 MG/2.5ML, SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Combivent UDV: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 02231675: Combivent UDV
Raw flags: notABenefit=Y, sec3=Y
Item: 120800050; group id 208; item number 0378; lccId 00029; manufacturer id BOE
Source form: Inh Sol-2.5mL Amp Pk; strength: 500mcg/2.5mg/2.5mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02231675
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51050Interchangeable products
Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 · $0.8066
Teva-Combo Sterinebs · DIN 02272695 · $0.8066
Shortage status: discontinued (January 8, 2020, reported by BOEHRINGER INGELHEIM (CANADA) LTD LTEE); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02231675
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 8, 2020 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (R03BB): coverage varies; not interchangeable
Aclidinium (Tudorza Genuair): general benefit
Glycopyrronium (Seebri Breezhaler): general benefit
Tiotropium (Spiriva): general benefit
Umeclidinium (Incruse Ellipta): general benefit
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (12:08 Parasympatholytic (Cholinergic Blocking) Agents) and how they are covered
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: ACLIDINIUM BROMIDE, BENZTROPINE MESYLATE, ETHOPROPAZINE HCL, GLYCOPYRRONIUM BROMIDE, PROCYCLIDINE HCL, TIOTROPIUM BROMIDE MONOHYDRATE, UMECLIDINIUM
Some products covered without a code (check the product listing): OXYBUTYNIN CHLORIDE, TRIHEXYPHENIDYL HCL
12:08 Parasympatholytic (Cholinergic Blocking) Agents
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered
Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL
Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE
52:36 Other Eye, Ear, Nose and Throat Agents
1 INDICATIONS
AA-IPRAVENT (ipratropium bromide inhalation solution) is indicated for:
• the treatment of bronchospasm associated with acute exacerbations of chronic obstructive
pulmonary disease (COPD), including chronic bronchitis and emphysema.
• the treatment of bronchospasm associated with acute severe exacerbations of bronchial
asthma when used in conjunction with a beta2 adrenergic agonist such as salbutamol.
AA-IPRAVENT inhalation solution must be administered by means of nebulizer using gas flow
(oxygen or compressed air).
1.1 Pediatrics
Pediatrics (<5 years of age): Based on the data reviewed by Health Canada, the efficacy and
safety of AA-IPRAVENT in children younger than 5 years have not been established.
1.2 Geriatrics
Geriatrics (≥65 years of age): Elderly patients can use AA-IPRAVENT at the recommended dose.
https://pdf.hres.ca/dpd_pm/00072339.PDF
PM date: AUG 12, 1994
Source product: AA-IPRAVENT; DIN 02126222; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE
TEVA-COMBO Sterinebs® (salbutamol sulphate and ipratropium bromide) Inhalation
Solution in unit dose vials is indicated for the management of bronchospasm in
patients suffering from chronic obstructive pulmonary disease (COPD) who require
regular treatment with both ipratropium and salbutamol.
Treatment should be initiated and administered under medical supervision, e.g.
in the hospital setting. Home based treatment can be recommended in exceptional
cases (severe symptoms or experienced patients requiring higher doses) when a
low dose rapid acting beta-agonist bronchodilator has been insufficient in
providing relief after consultation with an experienced physician.
Administration should be stopped when sufficient symptom relief is achieved.
Pediatrics:
The efficacy and safety in children and adolescents under 18 years has not been
established. TEVA-COMBO Sterinebs® (salbutamol sulphate and ipratropium bromide)
Inhalation Solution is not indicated in this patient population.
Geriatrics:
Page 3 of 48
Elderly patients can use TEVA-COMBO Sterinebs® (s…
https://pdf.hres.ca/dpd_pm/00033894.PDF
PM date: March 1, 2016
Source product: TEVA-COMBO STERINEBS; DIN 02272695; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Ipravent · DIN 02246084
Shortage status: active shortage (reported 2026-08-25, estimated to end 2026-10-30, last updated 2026-09-25); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246084
Atrovent · DIN 02163705
Shortage status: discontinued (2018-10-04, reported by SANOFI-AVENTIS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02163705
Atrovent · DIN 02163713
Shortage status: discontinued (2018-11-13, reported by SANOFI-AVENTIS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02163713
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules):
ODB 65 and over (seniors path)
Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗)
Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗)
Eligibility: Individual annual net income threshold
Program year August 1, 2026 to July 31, 2027: $25,480
This applies to a senior who:
does not have a spouse
has a married spouse with whom they no longer live in a conjugal relationship
has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗)
Eligibility: Combined annual net income requirement
Program year August 1, 2026 to July 31, 2027: $42,290
This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗)
Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗)
What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗)
Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗)
Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100.
That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year).
For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25.
Use this chart below to see what the deductible will be in your first year:
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)
Other review policies
For Ipravent, Atrovent, Atrovent UDV, Combivent UDV: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.